Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-10-16
2000-06-06
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3140
Patent
active
060719486
ABSTRACT:
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
REFERENCES:
patent: 2830991 (1958-04-01), Keller et al.
patent: 3560495 (1971-02-01), Frankus et al.
patent: 3563986 (1971-02-01), Frankus et al.
patent: 3625946 (1971-12-01), Koch et al.
patent: 3705162 (1972-12-01), Graudums et al.
patent: 4552888 (1985-11-01), Koppel et al.
patent: 4994443 (1991-02-01), Folkman et al.
patent: 5001116 (1991-03-01), Folkman et al.
patent: 5021404 (1991-06-01), Folkman et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5605914 (1997-02-01), Muller
Aronson, et al., "Thalidomide-Induced Peripheral Neuropathy. Effect of Serum Factor on Nerve Cultures", Arch. Dermatol., vol. 120, No. 11, pp. 1466-1470 (1984).
Bach, et al., "Thalidomide in Cancer Chemotherapy", The Lancet, vol. 1, p. 1271 (1963).
Barnhill, et al., "Thalidomide: Use and Possible Mode of Action in Reactional Lepromatous Leprosy and in Various Other Conditions", J. Am. Acad. Dermatol., vol. 7, No. 3, pp. 317-323 (1982).
Bensinger, W.I., "Supportive Care in Marrow Transplantation", Curr. Opin. Oncol., vol. 4, No. 4, pp. 614-623 (1992).
Bonnetblanc, et al., "Thalidomide and Recurrent Aphthous Stomatitis: a Follow-up Study", Dermatology, vol. 193, No. 4, pp. 321-323 (1996).
Boodman, S.G., "Questions About a Popular Prenatal Test", The Washington Post (1992).
Bowers, et al., "Effect of Thalidomide on Orogenital Ulceration", Br. Med. Journ., vol. 287, No. 6395, pp. 799-800 (1983).
Braun, et al., "Thalidomide Metabolite Inhibits Tumor Cell Attachment to Concanavalin a Coated Surfaces", Biochem. Biophys. Res. Comm., vol. 98, No. 4, pp. 1029-1034 (1981).
Brodthagen, H., "Significant Response of Oral Aphthosis to Thalidomide Treatment", J. Am. Acad. Dermatol., vol. 13, No. 3, p. 509 (1985).
Bubl, et al., "Dysphagia in Dermatologic Disease", Dysphagia, vol. 8, No. 2, pp. 85-90 (1993).
Bullock, W.E., "The Clinical Significance of Erythema Nodosum", Hosp. Pract., vol. 21, No. 3, pp. 102E-2H, 102K-2L, 102Q-2R pas (1986).
Burger, et al., "Epidermolysis Bullosa Acquisita, a Rare Late Complication of Allogeneicbone Marrow Transplantation?", Bone Marrow Transplant, vol. 9, No. 2, pp. 139-141 (1992).
Calnan, et al., "Actinic Prurigo (Hutchinson's Summer Prurigo)", Clin. Exp. Dermatol., vol. 2, No. 4, pp. 365-372 (1977).
Cant, J.S., "Minor Ocular Abnormalities Associated With Thalidomide", The Lancet, p. 1134 (1966).
Carmichael, et al., "Thalidomide: A Restricted Role", Lancet, vol. 339, No. 8805, p. 1362 (1992).
Chapon, et al., "Neuropathies Caused by Thalidomide", Rev. Neurol., vol. 141, No. 11, pp. 719-728 (1985).
Chosidow, O, et al., "Sclerodermatous Chronic Graft-Versus-Host Disease: Analysis of Sevencases", J. Am. Acad. Dermatol., vol. 26, No. 1, pp. 49-55 (1992).
Claydon, et al., "Gastrointestinal Emergenices in HIV Infection", Balliere's Clin Gastroennterol., vol. 5, No. 4, pp. 887-911 (1991).
Clemmensen, et al., "Thalidomide Neurotoxicity", Arch. Dermatol, vol. 120, No. 3, pp. 338-341 (1984).
Costa, et al., "Aseptic Adenitis in a Patient with Pyoderma Gangrenosum", Ann. Dermatol., vol. 121, No. 8, pp. 550-552 (1994).
Crawford, C.L., "Letter: Thalidomide in Erythema Nodosum Leprosum", Lancet, vol. 2, No. 839, pp. 1201-1202 (1973).
Crawford, C.L., "Treatmen tof Erythema Nodosum Leprosum with Thalidomide", Lancet, vol. 2, No. 828, pp. 567-568 (1973).
Crawford, C.L., "Use of Thalidomide in Leprosy [letter; comment]", BMJ, vol. 302, No. 6729, pp. 1603-1604 (1991).
Current Bibliographics in Medicine, "Thalidomide: Potential Benefits and Risks", National Inst. Health, National Library of Medicine, pp. 1-72 (Jan. 1963-Jul. 1997).
D'Amato, et al., "Angiogenesis Inhibition in Age-Related Macular Degeneration", Ophtalmology, vol. 102, No. 9, pp. 1261-1262 (1995).
D'Amato, et al., "Microscopic Analysis of Retinal-Vessels Utilizing Fluorescein-Labeled High-Molecular-Weight Dextrans", Invest. Opthamol. & Visual Science, vol. 33, No. 4, p. 1082 (1992).
Dark, et al., "Combretastin A-4, an Agent that Displays Potent and Selective Toxicity Toward Tumor Vasculature", Cancer Research, vol. 37, pp. 1829-1834 (1997).
David-Bajar, K.M., "Subacute Cutaneous Lupus Erythematosus", J. Invest. Dermatol. vol. 100, No. 1, pp. 2s-8s (1993).
DeKlerk, et al., "New Methods of Treatment for Renal Allotransplants Using the Baboon as a Primate Experimental Model", J. Urol. vol. 102, No. 5, pp. 532-540 (1969).
Dhodapkar, et al., "A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients with Multiple Myeloma", UARK 98-003, pp. 1-15.
DiPaolo, et al., "Thalidomide: Effects on Ehrlich Ascites Tumor Cells in vitro", Science, vol. 144, pp. 1583 (1964).
DiPaolo, "Effect of Thalidomide on a Variety of Transplantable Tumors", Cancer Chemo. Reports, vol. 29, pp. 99-102 (1963).
DiPaolo, "In Vitro Test Systems for Cancer Chemotheraphy. II. Correlation of In Vitro Inhibition of Dehydrogenase and Growth with In Vivo Inhibition of Ehrlich Ascites Tumor", P.S.E.B.M., vol. 114, pp. 384-387 (1963).
DiPaolo et al., "Teratogenesis-oncogenesis: A Study of Possible Relationships", Arch. Path., vol. 81, pp. 3-23 (1966).
Dunn, et al., "Bone Marrow Transplantation and Cataract Development", Arch. Ophthalmol. vol. 111, No. 10, pp. 1367-1373 (1993).
(Editorial) "Thalidomide in Dermatology and Leprosy", Lancet, vol. 2, No. 8446, pp. 80-81 (1985).
(Editorial) "Thalidomide Tested for Treatment of AIDS", U.S. Pharm., vol. 18, No. 8, p. 14 (1993).
Elia, et al., "Giant Esophageal Ulcer Treated with Steroids in AIDS Patient(2)", J. Acquired Immune Defic. Syndr., vol. 5, No. 8, pp. 848-849 (1992).
Eriksson, et al., "Drug Exposure and Flow Cytometry Analyses in a Thalidomide Treatment Schedule that Prolongs Rat Cardiac Graft Survival", Transplant Proc., vol. 24, No. 6, pp. 2560-2561 (1992).
Fajardo, et al., "Dual Role of Tumor Necrosis Factor-.alpha. in Angiogenesis", Am. J. Pathol., vol. 140, No. 3, pp. 539-544 (1992).
Faure, et al., "PMN Leukocytes Chemotaxis: inhibition by Thalidomide", Pathol. Biol. (Paris), vol. 29, No. 10, pp. 601-604 (1981).
Faure, et al., "Inhibition of PMN Leukocytes Chemotaxis by Thalidomide", Arch. Dermatol. Res., vol. 269, No. 3, pp. 275-280 (1980).
Francois, J., "Embryological Pigment Epithelial Dystrophies", Opthalmologica, vol. 172, pp. 417-433 (1976).
Fuller, et al., "Thalidomide, Peripheral Neuropathy and AIDS", Int. J. STD AIDS, vol. 2, No. 5, pp. 369-370 (1991).
Furner,, B.B., "Treatment of Subacute Cutaneous Lupus Erythematosus", Int. J. Dermatol., vol. 29, No. 8, pp. 542-547 (1990).
Gad, et al., "Thalidomide Induces Imbalances in T-Lymphocyte Sub-Populations in the Circulating Blood of Healthy Males", Lepr. Rev. , vol. 56, No. 1, pp. 35-39 (1985).
Genvo, et al., "Treatment of Aphthosis with Thalidomide and with Colchicine", Dermatologica, vol. 168, No. 4, pp. 182-188 (1984).
Geoghiou, et al., "HIV-Associated Oesophageal Ulcers Treated with Thalidomide", Med. J. of Australia, vol. 152, pp. 382-383 (1990).
Gershbein, "Effect of Transplanted Tumor and Various Agents on Liver Regeneration During Pregnancy", P.S.E.B.M., vol. 126, pp. 88-92 (1967).
Goihman-Yahr, M., et al., "Autoimmune Diseases and Thalidomide II. Adjuvant Disease, Experimental Allergic Encephalomyelitis and Experimental Allergic Neuritis of the Rat", Int. J. Leprosy, vol. 42, No. 3, pp. 266-275 (1974).
Gorin, I.,et al., "Thalidomide May Cure AIDS Ulcers", Nurs. Times, vol. 86, No. 24, p. 10 (1990).
Gorin, I., et al., "Thalidomide in Hyperalgic Pharyngeal Ulceration of AIDS", Lancet, vol. 335, p. 1343 (1990).
Goulden, V., et al., "Linear Prurigo Simulating Dermatitis Artefacta in Dominant Dystrophicepidermolysis Bullosa", Br. J. Dermatol., vol. 129, No. 4, pp. 443-446 (1993).
Grinspan, et al., "Treatment of Aphthae with Thalidomide", J. Am. Acad. Dermatol., vol. 20, No. 6, pp. 1060-1063 (1989).
Grosshans, E., et a
Goldberg Jerome D.
The Children's Medical Center Corporation
LandOfFree
Methods and compositions for inhibition of angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibition of angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibition of angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2214021